Form 4: Esperion Therapeutics Director Robert Hoffman Granted Stock Options

Director Robert E. Hoffman of Esperion Therapeutics, Inc. was granted stock options to purchase 40,000 shares of common stock on April 1, 2025.

Summary

• Robert E. Hoffman, a director of Esperion Therapeutics, Inc., was granted stock options on April 1, 2025.
• The options allow him to purchase 40,000 shares of common stock at an exercise price of $1.41 per share.
• The options vest in equal annual installments over a three-year period, beginning on April 1, 2026.
• The options expire on April 1, 2035.
• Hoffman also has granted a Limited Power of Attorney to Sheldon Koenig and Benjamin Looker to execute SEC filings on his behalf.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate action (granting stock options) which is generally viewed positively as it aligns management and shareholder interests. The sentiment is neutral to slightly positive.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the granting of stock options suggests an expectation of future value creation.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock price.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options to incentivize their directors and officers.
• The vesting schedule of three years is typical for stock option grants in this sector.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to increase shareholder value.
• Employees may see the grant as a sign of confidence in the company's future prospects.

Key Dates

Keywords

stock options, Esperion Therapeutics, director, Robert E. Hoffman, Form 4, beneficial ownership, securities, power of attorney